{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-26-000047","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2026-10-20T12:33:25+00:00","discovered_at":"2026-10-20T12:35:00.287993+00:00","generated_at":"2026-10-20T12:35:06.675993+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus reports ARC-20 casdatifan data: 1L PFS 69% at 12 months, 2L median PFS 14.5 months","bullets":["First-line casdatifan + zimberelimab (n=30): 50% confirmed ORR, 86%/69% landmark PFS at 6/12 months, 6.7% primary progression; median follow-up 11.5 months.","Second-line casdatifan + cabozantinib (n=43): median PFS 14.5 months, 18-month OS 77%, cORR 44%, primary progression 5%; median follow-up 21.3 months.","Late-line casdatifan monotherapy (n=121): median OS 35 months, median PFS 13 months, cORR 36% across four pooled cohorts with 28 months median follow-up.","Casdatifan + ipilimumab + zimberelimab: 1 of 24 scanned patients (4%) had primary progression at 3 months; 31 dosed, no unexpected safety signals.","Data cutoff Sept 4, 2026; presented Oct 20, 2026. No unexpected safety signals in any cohort; Grade 3+ immune-mediated AEs consistent with ipilimumab/nivolumab."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-26-000047","json":"https://secwatch.observer/filing/0001724521-26-000047.json","markdown":"https://secwatch.observer/filing/0001724521-26-000047.md","text":"https://secwatch.observer/filing/0001724521-26-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000047/0001724521-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000047/rcus-20261020.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-20T12:35:06.675993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}